Collegium Pharmaceutical, Inc. (COLL): Price and Financial Metrics

Collegium Pharmaceutical, Inc. (COLL): $35.71

0.68 (-1.87%)

POWR Rating

Component Grades








Add COLL to Watchlist
Sign Up

COLL Price/Volume Stats

Current price $35.71 52-week high $40.95
Prev. close $36.39 52-week low $20.83
Day low $35.47 Volume 380,300
Day high $36.51 Avg. volume 439,790
50-day MA $36.59 Dividend yield N/A
200-day MA $27.99 Market Cap 1.17B

COLL Stock Price Chart Interactive Chart >

Collegium Pharmaceutical, Inc. (COLL) Company Bio

Collegium Pharmaceuticals is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain and other diseases. The company was founded in 2002 and is based in Canton, Massachusetts.

COLL Latest News Stream

Event/Time News Detail
Loading, please wait...

COLL Latest Social Stream

Loading social stream, please wait...

View Full COLL Social Stream

Latest COLL News From Around the Web

Below are the latest news stories about COLLEGIUM PHARMACEUTICAL INC that investors may wish to consider to help them evaluate COLL as an investment opportunity.

Collegium Pharmaceutical Inc CEO Joseph Ciaffoni Sells Company Shares

On December 21, 2023, Joseph Ciaffoni, President and CEO of Collegium Pharmaceutical Inc (NASDAQ:COLL), executed a sale of 4,357 shares of the company.

Yahoo | December 23, 2023

Collegium Pharmaceutical Inc CEO Joseph Ciaffoni Sells 68,768 Shares

Joseph Ciaffoni, the President and CEO of Collegium Pharmaceutical Inc (NASDAQ:COLL), sold 68,768 shares of the company on December 20, 2023, according to a recent SEC filing.

Yahoo | December 21, 2023

Collegium Pharmaceutical (NASDAQ:COLL) ascends 8.3% this week, taking five-year gains to 77%

The main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up...

Yahoo | December 14, 2023

Insider Sell: EVP and General Counsel Shirley Kuhlmann Sells 25,600 Shares of Collegium ...

Shirley Kuhlmann, the Executive Vice President and General Counsel of Collegium Pharmaceutical Inc, has recently sold 25,600 shares of the company's stock.

Yahoo | November 30, 2023

Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent

STOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the judgment of the Patent Trial and Appeal Board (PTAB) in its final decision that Purdue’s ‘961 patent, which Purdue has claimed is infringed by Xtampza® ER, is invalid. The Federal Circuit’s decision affirming the invalidity of Purdue’s ‘961 patent confirms b

Yahoo | November 27, 2023

Read More 'COLL' Stories Here

COLL Price Returns

1-mo -8.65%
3-mo N/A
6-mo 62.61%
1-year 55.73%
3-year 52.22%
5-year 147.99%
YTD 16.02%
2023 32.67%
2022 24.20%
2021 -6.74%
2020 -2.67%
2019 19.86%

Continue Researching COLL

Here are a few links from around the web to help you further your research on Collegium Pharmaceutical Inc's stock as an investment opportunity:

Collegium Pharmaceutical Inc (COLL) Stock Price | Nasdaq
Collegium Pharmaceutical Inc (COLL) Stock Quote, History and News - Yahoo Finance
Collegium Pharmaceutical Inc (COLL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!